Drug or treatment

Amivantamab clinical trials

• 18Clinical trials
• 33Countries

Newest trials

All recruiting trials (18)

• Amivantamab with intrathecal pemetrexed for leptomeningeal metastasis from EGFR-mutated lung adenocarcinoma

  This study tests whether giving amivantamab with intrathecal pemetrexed is safe and may help treat leptomeningeal metastasis in adults with EGFR-mutant lung cancer.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07744529

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• Amivantamab plus single‑agent chemotherapy for advanced non‑small cell lung cancer with EGFR exon 20 insertion in people unable to receive platinum

  This trial will test whether adding amivantamab to a single chemotherapy drug helps people with metastatic non‑small cell lung cancer that has an EGFR exon 20 insertion who cannot get platinum chemotherapy.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, Roma (RM) · NCT07392658

• Amivantamab added to pembrolizumab and platinum chemotherapy versus pembrolizumab with platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial will see if adding amivantamab to pembrolizumab and platinum‑based chemotherapy helps adults with recurrent or metastatic head and neck squamous cell carcinoma who have not yet had systemic treatment in the metastatic setting.

  Recruiting at 205 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 204 other locations · NCT07276399

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

• Amivantamab plus olomorasib for metastatic KRAS G12C non-small cell lung cancer

  This trial tests whether combining amivantamab and olomorasib can slow tumor growth in people with metastatic non-small cell lung cancer that has a KRAS G12C mutation after platinum chemotherapy and PD‑L1 immunotherapy.

  Recruiting at 12 sites Phase 1/2 Janssen Research & Development, LLC · New York, New York and 11 other locations · NCT07227025

• Amivantamab plus hyaluronidase versus cetuximab for advanced cutaneous squamous cell carcinoma in people with weakened immune systems

  This phase II trial tests whether amivantamab with hyaluronidase works better than cetuximab for people with recurrent or metastatic cutaneous squamous cell carcinoma who have a weakened immune system.

  Recruiting at 59 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 58 other locations · NCT07042295

• Combining ORIC-114 with Amivantamab for NSCLC with EGFR Exon 20 Insertion Mutations

  This study is testing a new combination of two drugs, ORIC-114 and amivantamab, to see if they can help people with advanced lung cancer that has a specific genetic mutation.

  Recruiting at 2 sites Phase 1 ORIC Pharmaceuticals · New York, New York and 3 other locations · NCT06816992

• Preoperative treatment for lung cancer with amivantamab and chemotherapy

  This study is testing if giving a new antibody treatment called amivantamab before surgery can help patients with certain types of lung cancer feel better and improve their outcomes.

  Recruiting at 4 sites Phase 2 University Hospital, Essen · Hasselt and 3 other locations · NCT06784791

• Comparing Amivantamab with FOLFIRI to Cetuximab/Bevacizumab with FOLFIRI for Colorectal Cancer

  This study is testing if a new treatment combining amivantamab with FOLFIRI can help people with certain types of colorectal cancer live longer and feel better compared to the standard treatment with cetuximab or bevacizumab plus FOLFIRI.

  Recruiting at 235 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 250 other locations · NCT06750094

• Combining Amivantamab with Lazertinib or Chemotherapy for Advanced Lung Cancer

  This study tests if a new combination of amivantamab with lazertinib or chemotherapy can help people with advanced lung cancer that has certain genetic changes.

  Recruiting at 68 sites Phase 2 Janssen Research & Development, LLC · Daphne, Alabama and 204 other locations · NCT06667076

• Comparing two treatments for advanced left-sided colorectal cancer

  This study is testing whether a new drug called amivantamab combined with standard chemotherapy works better than cetuximab with the same chemotherapy for people with advanced left-sided colorectal cancer that can't be surgically removed.

  Recruiting at 233 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 238 other locations · NCT06662786

• Testing amivantamab for recurrent or metastatic head and neck cancer

  This study is testing if a new drug called amivantamab, alone or with other treatments, can help people with recurrent or metastatic head and neck cancer feel better.

  Recruiting at 51 sites Phase 1/2 Janssen Research & Development, LLC · La Jolla, California and 55 other locations · NCT06385080

• Understanding resistance to amivantamab in lung cancer patients

  This study is trying to understand why some lung cancer patients with a specific mutation stop responding to the drug amivantamab, by looking at their blood and tumor samples after their disease gets worse.

  Recruiting at 10 sites Groupe Francais De Pneumo-Cancerologie · Bordeaux and 17 other locations · NCT06247826

• Targeted treatment for advanced lung cancer with MET gene amplification

  This study is testing if a new treatment called amivantamab can help people with advanced lung cancer that has extra copies of the MET gene feel better and live longer.

  Recruiting at 250 sites Phase 2 SWOG Cancer Research Network · Jonesboro, Arkansas and 270 other locations · NCT06116682

• Evaluating amivantamab for advanced non-small cell lung cancer

  This study is testing if a new treatment combining amivantamab and another drug can help people with advanced non-small cell lung cancer, especially those with certain genetic mutations.

  Recruiting at 82 sites Phase 2 Janssen Research & Development, LLC · La Jolla, California and 109 other locations · NCT05498428

• Amivantamab treatment for advanced colorectal cancer

  This study is testing if a new drug called amivantamab, alone or with regular chemotherapy, can help people with advanced colorectal cancer.

  Recruiting at 44 sites Phase 1/2 Janssen Research & Development, LLC · Birmingham, Alabama and 52 other locations · NCT05379595

Quick answers

How many clinical trials of Amivantamab are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in United States (12 trials), Germany (9 trials), Spain (9 trials), China (9 trials), Italy (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1/2: 4, Phase 3: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →